Gastrointestinal Cancer

Oncology nurses can assess patients’ risk factors and advocate for preventive strategies that protect kidney function during cisplatin therapy.

Further data could back zanidatamab as advanced treatment for HER2-positive advanced gastroesophageal adenocarcinoma.

The novel MEK inhibitor atebimetinib plus chemotherapy showed early signs of survival benefit in first-line treatment of patients with pancreatic cancer.

The novel antibody-drug conjugate EBC-129 has been fast tracked by the FDA for approval in pancreatic ductal adenocarcinoma.

Adding panitumumab to neoadjuvant FOLFOX cut recurrence risk and improved survival in locally advanced, RAS/BRAF wild-type colon cancer.

Retifanlimab has received approval for the frontline treatment of advanced anal cancer from the FDA.

Assessing the signs and symptoms of chemotherapy-induced diarrhea and providing accurate and timely patient education may reduce complications and optimize survival outcomes.

The FDA approved cabozantinib for use in patients with previously treated unresectable, locally advanced or metastatic, well-differentiated epNETs or pNETs.

Maintenance treatment with OSE2101 plus FOLFIRI following induction chemotherapy with FOLFIRINOX yielded promising results in patients with advanced/metastatic PDAC.

T-DXd delivered an OS benefit for patients with unresectable or metastatic HER2-positive gastric and GEJ adenocarcinoma following trastuzumab-based treatment.

The FDA approved tislelizumab-jsgr (Tevimbra) with platinum chemotherapy as a first-line treatment for adults with PD-L1-positive, unresectable or metastatic esophageal squamous cell carcinoma.

Perioperative chemotherapy improved survival compared with preoperative chemoradiotherapy in managing esophageal cancer.

The NCCN updated its guidelines to clarify the role of ctDNA as a biomarker for recurrence risk in colon and rectal cancer and for disease monitoring in Merkel cell carcinoma.

Envafolimab plus suvemcitug and FOLFIRI showed early efficacy and manageable safety in MSS/pMMR colorectal cancer, according to phase 2 trial data.

Thermal ablation was associated with no treatment-related deaths and fewer AEs compared to surgical resection in patients with CRC liver metastases.

In BRAF V600E-mutant metastatic colorectal cancer, encorafenib plus cetuximab and mFOLFOX6 improved PFS and OS compared with chemotherapy.

Sintilimab with neoadjuvant chemoradiotherapy enhanced pCR rates in resectable, locally advanced esophageal squamous cell carcinoma.

The combination of tislelizumab, irinotecan, paclitaxel, oxaliplatin, and 5-FU/leucovorin demonstrated promising efficacy and manageable safety in gastric and GEJ cancers.

The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with HER2-positive gastric cancers enrolled in the INNOVATION trial.

Managing weight loss with telotristat ethyl in patients with metastatic pancreatic ductal adenocarcinoma may improve survival, although further research is needed.

Phone calls to follow up with patients with locally advanced esophageal squamous cell carcinoma while at home may reduce AEs like stomatitis before the first outpatient clinic visit.

Phase 2 findings show clinical responses and improved survival with evorpacept in patients with HER2-positive gastric/gastroesophageal cancer.

The phase 2 FDZL-001 trial showed high overall survival and progression-free survival rates with camrelizumab plus Nab-POF in patients with gastric/GEJ cancer.

The EA2186 trial was the first study specifically designed to test chemotherapy in older adults with advanced pancreatic cancer who were considered vulnerable.

Analysis of the NAPOLI 3 trial showed that lower doses of liposomal irinotecan or oxaliplatin did not reduce survival in patients with pancreatic ductal adenocarcinoma.

First-line nivolumab plus ipilimumab was shown to be effective and well-tolerated in patients with unresectable hepatocellular carcinoma in the CheckMate 9DW study.

Cabozantinib prolonged PFS compared to placebo for patients with extrapancreatic NETs starting in the GI tract in a subgroup analysis of the CABINET trial.

Preoperative sintilimab with chemoradiotherapy boosted pathological complete response rates in patients with resectable, locally advanced esophageal squamous cell carcinoma.

Findings from this survey also demonstrated that 23% of providers were comfortable with interpreting biomarker testing results for treatment decision-making.

The phase 3 RATIONALE-306 study found no significant difference in overall survival benefits from tislelizumab plus chemotherapy between early and late responders with ESCC.